WNT16 and prostate carcinoma: There are, however, notable reports of WNT-16B/β-catenin signaling: Mouse WNT-16 was described to have a weak agonistic efficacy in WNT/β-catenin signaling in MC3T3 mouse osteocyte precursor cells54, and WNT-16B promoted chemotherapy resistance via activation of β-catenin signaling in human prostate cancer cells55.